COVAX Announces new agreement, plans for first deliveries
Evidence-supported stage: announced.
Stage as of 2021-01-22. Automated extraction; independent review has not been recorded.
Identity and parties
individual_source_item
Parties not established by the retained evidence
Extraction basis: automated_explicit_source_text.
A source reference may describe an existing instrument, a proposal or several instruments. Separate references are not counts of distinct agreements. A signing does not establish implementation, and missing later evidence does not establish failure or abandonment.
Evidence timeline
| Stage stated | Date | Date basis | Evidence |
|---|---|---|---|
| announced | 2021-01-22 | dated_source_announcement_publication | COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine Source statement Source tier: official_government; office: who-dg |
| announced | 2021-01-22 | explicit_date_in_source_text | Click here for the latest COVAX supply forecast Geneva/Oslo 22 January 2021 – COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO emergency use listing. Source statement Source tier: official_government; office: who-dg |
Source references
- COVAX Announces new agreement, plans for first deliveries. COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements. Additionally, COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in Q1 2021, via existing agreements with the Serum Institute of India (SII) and AstraZeneca. COVAX is therefore on track to deliver at least 2 billion doses by the end of the year, including at least 1.3 billion doses to 92 lower income economies in the Gavi COVAX AMC. Click here for the latest COVAX supply forecast Geneva/Oslo 22 January 2021 – COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO emergency use listing. Rollout will commence with the successful negotiation and execution of supply agreements. In further support of its mission to expedite early availability of vaccines to lower-income countries and help bring a rapid end to the acute stage of the COVID-19 pandemic, COVAX also confirmed today that it will exerc Read source 2021-01-22 · source_publication
- COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine Read source 2021-01-22 · dated_source_announcement_publication
- Click here for the latest COVAX supply forecast Geneva/Oslo 22 January 2021 – COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO emergency use listing. Read source 2021-01-22 · explicit_date_in_source_text
Retained reference ID: agreement-24fcc9c9d305a08ab958. Related records: 05bbb1b5e921763181ebdfd0.
Submit evidence or a correction · Follow-through tracker · Snapshot downloads